BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression

Simple Summary Bruton’s Tyrosine Kinase (BTK) was originally considered to be primarily expressed in cells of hematopoietic origin. Apart from the 77 kDa BTK isoform expressed in immune cells, elevated expression of novel BTK isoforms of 80 and 65 kDa have been recently described for several solid tumor entities. These newly described isoforms have been linked to tumor growth and poor prognosis. Therefore, we aimed to investigate whether BTK isoforms are also expressed in head and neck squamous cell carcinoma (HNSCC) and further the molecular and cellular consequences of BTK expression for HNSCC tumorigenesis. We confirmed the expression of the BTK-p65 and BTK-p80 isoforms in HNSCC and revealed that both isoforms are products of the same mRNA. Abrogation of BTK activity inhibited tumor progression in our study. Thus, targeting BTK activity appears as a promising therapeutic option for patients suffering from BTK expressing HNSCC. Abstract Here, we describe the expression of Bruton’s Tyrosine Kinase (BTK) in head and neck squamous cell carcinoma (HNSCC) cell lines as well as in primary HNSCC samples. BTK is a kinase initially thought to be expressed exclusively in cells of hematopoietic origin. Apart from the 77 kDa BTK isoform expressed in immune cells, particularly in B cells, we identified the 80 kDa and 65 kDa BTK isoforms in HNSCC, recently described as oncogenic. Importantly, we revealed that both isoforms are products of the same mRNA. By investigating the mechanism regulating oncogenic BTK-p80/p65 expression in HNSSC versus healthy or benign tissues, our data suggests that the epigenetic process of methylation might be responsible for the initiation of BTK-p80/p65 expression in HNSCC. Our findings demonstrate that chemical or genetic abrogation of BTK activity leads to inhibition of tumor progression in terms of proliferation and vascularization in vitro and in vivo. These observations were associated with cell cycle arrest and increased apoptosis and autophagy. Together, these data indicate BTK-p80 and BTK-p65 as novel HNSCC-associated oncogenes. Owing to the fact that abundant BTK expression is a characteristic feature of primary and metastatic HNSCC, targeting BTK activity appears as a promising therapeutic option for HNSCC patients.

[1]  Jinny Park,et al.  Downregulation of matriptase suppresses the PAR-2/PLCγ2/PKC-mediated invasion and migration abilities of MCF-7 breast cancer cells , 2021, Oncology reports.

[2]  E. Kostareli,et al.  The role of Bruton's tyrosine kinase in the immune system and disease , 2021, Immunology.

[3]  M. Cerrito,et al.  p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors , 2021, Frontiers in Cell and Developmental Biology.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  Wei-Hwa Lee,et al.  Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness , 2021, Oncogenesis.

[6]  C. R. Leemans,et al.  Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.

[7]  Chun Kit Yeung,et al.  MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling , 2020, Life Science Alliance.

[8]  R. Marienfeld,et al.  Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells , 2019, Laryngo-Rhino-Otologie.

[9]  T. Clauditz,et al.  Analyzing expression and phosphorylation of the EGF receptor in HNSCC , 2019, Scientific Reports.

[10]  I. Amelio,et al.  Clinical update on head and neck cancer: molecular biology and ongoing challenges , 2019, Cell Death & Disease.

[11]  S. Vicent,et al.  p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma , 2019, Journal of experimental & clinical cancer research : CR.

[12]  F. Puglisi,et al.  Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer , 2019, Cancers.

[13]  M. Papa,et al.  Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype , 2019, Front. Mol. Neurosci..

[14]  R. Hendriks,et al.  Role of Bruton’s tyrosine kinase in B cells and malignancies , 2018, Molecular Cancer.

[15]  A. Weber,et al.  Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity , 2017, Front. Immunol..

[16]  R. Joseph,et al.  Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts. , 2017, Structure.

[17]  Peng Zhao,et al.  Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma , 2017, Journal of Experimental & Clinical Cancer Research.

[18]  R. Mesía,et al.  Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. , 2016, Oral oncology.

[19]  R. Roskoski.  Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. , 2016, Pharmacological research.

[20]  M. Hsiao,et al.  Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes , 2016, Oncotarget.

[21]  F. Tao,et al.  Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth. , 2016, American journal of translational research.

[22]  Christopher J. Sevinsky,et al.  Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells , 2016, Molecular Cancer Therapeutics.

[23]  S. Bonin,et al.  A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation , 2015, Oncogene.

[24]  Christopher J. Sevinsky,et al.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer , 2015, Cancer biology & therapy.

[25]  C. Yuan,et al.  Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer , 2015, Oncotarget.

[26]  S. Fröhling,et al.  HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. , 2014, Cancer research.

[27]  K. Lam,et al.  Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor , 2014, Cell Death and Disease.

[28]  J. Burger.  Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials , 2014, Current Hematologic Malignancy Reports.

[29]  R. Lamont,et al.  Establishment and characterization of a telomerase immortalized human gingival epithelial cell line. , 2013, Journal of periodontal research.

[30]  M. Gerdes,et al.  A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis , 2013, Genes, chromosomes & cancer.

[31]  Juswinder Singh,et al.  Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[32]  Carsten Wiuf,et al.  Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis , 2011, BMC Genomics.

[33]  T. Kiyono,et al.  Immortalization and characterization of normal oral epithelial cells without using HPV and SV40 genes , 2011 .

[34]  U. Knippschild,et al.  Kinases as targets in the treatment of solid tumors. , 2010, Cellular signalling.

[35]  J. Gutkind,et al.  Dysregulated molecular networks in head and neck carcinogenesis. , 2009, Oral oncology.

[36]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[37]  M. Waterman,et al.  Wnt Activation and Alternative Promoter Repression of LEF1 in Colon Cancer , 2006, Molecular and Cellular Biology.

[38]  N. Okada,et al.  Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: relationship between clinicopathological appearances and cell proliferation. , 2006, Oral oncology.

[39]  K. Lu,et al.  Regulation of Bruton Tyrosine Kinase by the Peptidylprolyl Isomerase Pin1* , 2006, Journal of Biological Chemistry.

[40]  T. Wirth,et al.  Bruton's Tyrosine Kinase is involved in innate and adaptive immunity. , 2005, Histology and histopathology.

[41]  Xiang Guo,et al.  Head and neck cancers. , 2003, Cancer chemotherapy and biological response modifiers.

[42]  B. Palsson,et al.  Human Cell Culture , 2002, Human Cell Culture.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  R. Rabin,et al.  Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein , 2001, Nature Immunology.

[45]  C. Gerharz,et al.  Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. , 1999, Anticancer research.

[46]  W. B. Archey,et al.  Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3. , 1999, Cancer research.

[47]  P. Hawkins,et al.  Phosphatidylinositol 3-kinase-γ activates Bruton’s tyrosine kinase in concert with Src family kinases , 1997 .

[48]  R. Hendriks,et al.  B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. , 1994, The Journal of biological chemistry.

[49]  T. Kawakami,et al.  The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[52]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.